Corcept Therapeutics (CORT) Tops Q2 EPS by 6c; Raises Rev Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.22 --0%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.13, $0.06 better than the analyst estimate of $0.07. Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.53 million.
2017 revenue guidance increased by $20 million, to $145-155 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- GCI Liberty, Inc. (GLIBA) Tops Q3 EPS by 94c
- Ralph Lauren (RL) Tops Q2 EPS by 41c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
